EMIF-AD MBD

Before 2015

Europe

Maastricht University, Oxford University, Janssen Pharmaceutica, University of Lübeck, Kings College London, Gothenburg University, University of Antwerp, VU medical center Amsterdam.

Data and sample providers: Amsterdam, Antwerp, Barcelona IDIBAPS, Barcelona St Pau, DESCRIPA, EDAR, Gothenburg, Lausanne, Leuven, PharmaCog, San Sebastian GAP.

The present study was conducted as part of the EMIF-AD project which has received support from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement n° 115372, the resources of which are composed of financial contribution from the European Union’s Seventh Framework Program (FP7/2007–2013) and EFPIA companies’ in kind contribution.

Bos, I., Vos, S., Vandenberghe, R. et al. The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. Alz Res Therapy 10, 64 (2018). https://doi.org/10.1186/s13195-018-0396-5

Shi L, Xu J, Green R, et al. Multiomics profiling of human plasma and cerebrospinal fluid reveals ATN-derived networks and highlights causal links in Alzheimer's disease. Alzheimers Dement. 2023; 19(8): 3350-3364. doi:10.1002/alz.12961

Westwood S, Baird AL, Anand SN, et al. Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer’s Disease Multimodal Biomarker Discovery Cohort. Journal of Alzheimer’s Disease. 2020;74(1):213-225. doi:10.3233/JAD-190434

Morgan AR, Touchard S, Leckey C, O'Hagan C, Nevado-Holgado AJ, NIMA Consortium, et al. Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimers Dement. 2019; 15: 776-787. doi:https://doi.org/10.1016/j.jalz.2019.03.007

https://www.emif.eu/emif-ad-2/

https://bioportal.bioontology.org/ontologies/EMIF-AD